|
Post by lorcan458 on Feb 19, 2016 10:55:24 GMT -5
Given the gap between the EYES and Mannkind timing, I think Al needed the time put the final pieces in place for Mannkind going forward. I expect we'll hear a much bigger story within a few weeks, partnership or sale.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 19, 2016 11:07:49 GMT -5
No one is buying MNKD without the trial data from SNY. Do you guys see what happens when you invest in user reviews? No ones paying a premium for MNKD based of Adam Lasher and Sam Finta twitter reviews........
|
|
|
Post by BlueCat on Feb 19, 2016 11:09:29 GMT -5
Folks - Old Mann is 91. He dropped out of EYES, and now 'effective immediately', MKND too.
He seems like the sort who would work til the last because its what he loves. Remember Jobs 'effective immediately' ?
Wish all the best to him and his family. His making the change now is to keep it orderly.
Any bashers suggesting in the media a 'back turn' would be immediately ridiculed as a consummate idiot. More likely, they will be nicey to him (like they have been to Afrezza working as a drug), and then turn around and FUD the future of the company now.
And as for hope - as much as we may hope its because of a stock-changing event on the horizon for us, I'm thinking its just a common human reality. And one that all of us knew would come some day soon.
Now - what happens as a result of this change - this shall be very interesting indeed.
|
|
|
Post by BlueCat on Feb 19, 2016 11:17:21 GMT -5
|
|
|
Post by saxcmann on Feb 19, 2016 11:32:08 GMT -5
I think it's more likely now that we get sold. Possibly someone wanted Al off the BOD and not attached to company before bidding? But yes, poor health could also be reason.
|
|
|
Post by agedhippie on Feb 19, 2016 12:16:31 GMT -5
Maybe he felt that he and his wife did not have a lot of years remaining and they would rather spend the time each other rather than NASDAQ. I doubt there will be much change since he seems to have been hands off for a while now. The only change is that this probably kills the idea of Al riding to the rescue with checkbook in hand (not that I ever thought that was realistic anyway).
|
|
|
Post by nemzter on Feb 19, 2016 12:25:03 GMT -5
At least he's under the age of 80
|
|
|
Post by BlueCat on Feb 19, 2016 12:32:06 GMT -5
Anyone marrying him at this stage was up for playing with business and philanthropy for fun.
But none of this prevents him from contributing at ANY point. He may retire, but game is certainly not over for his contribution as a current majority stockholder.
|
|
|
Post by LosingMyBullishness on Feb 19, 2016 12:56:34 GMT -5
Is this viewed as a positive or a negative? Neutral by the market and surely negative by Al Mann himself. I doubt that he was involved in running the company for the last months but that he cared a lot. Last time I saw a public appearance was at the gala last year. He was holding up the chart with the comparison of profiles we all know and reiterated that this is all it takes to see the benefits of Afrezza. Well, we know now that it takes much, much more for MNKD to succeed in this market. I guess that he is very unhappy to leave the ship before the success he foresees has materialised. But already he has achieved more than most of us ever will and surely has contributes more to mannkind than the shrek-alikes.
|
|
|
Post by lakers on Feb 19, 2016 13:20:26 GMT -5
Last Nov BoD resulted in Hakan forced to resign. 2/18/16 BoD resulted in Al's resignation as Exec CoB. Hmm.
|
|
|
Post by BlueCat on Feb 19, 2016 13:37:27 GMT -5
Last Nov BoD resulted in Hakan forced to resign. 2/18/16 BoD resulted in Al's resignation as Exec CoB. Hmm. Right. He dropped out of active EYES involvement, took some time to cleanup with MNKD, and now needed to resign immediately and the board must elect the new Chair. What are you suggesting?
|
|
|
Post by BlueCat on Feb 19, 2016 13:38:19 GMT -5
Not to mention, the timing is good so they can speak to it at RBC and then the quarterly cc. Only a few days of weirdness possible.
|
|
|
Post by dreamboatcruise on Feb 19, 2016 13:53:13 GMT -5
No one is buying MNKD without the trial data from SNY. Do you guys see what happens when you invest in user reviews? No ones paying a premium for MNKD based of Adam Lasher and Sam Finta twitter reviews........ The clamp studies? Those are basically extended versions of what has already been done. I'm sure no company would buy MNKD until after full rights to Afrezza have transitioned back, but the data from the completed trials I doubt is a significant factor.
|
|
|
Post by mnholdem on Feb 19, 2016 14:23:29 GMT -5
By contractual agreement, MannKind already has access to that data anyway. Sanofi could not have withheld it or they would have been in breach.
|
|
|
Post by mnkdfann on Feb 19, 2016 14:45:57 GMT -5
Given the gap between the EYES and Mannkind timing, I think Al needed the time put the final pieces in place for Mannkind going forward. I expect we'll hear a much bigger story within a few weeks, partnership or sale. Myself, I doubt the few days of separation between announcements means anything more than someone on vacation not being available to sign a form, or write up a press release, as quickly as was done at the other company. Or maybe even more likely, they just spaced the announcements out so one did not detract from the other; two chances to praise Al and get him in the news instead of just once.
|
|